Agronomists discussing in a maize field by a refuge-planting sign
Commercial Strategy · Capital Allocation

Stop pet projects. Allocate towards opportunity.

How to actually use the bubble chart the big consultancies built, and that portfolios abandon the moment project championship kicks in.

Michiel de Jongh
Michiel de Jongh
Founder, Valorem Management  ·  June 2026  ·  6 min read

Walk into your average portfolio review at an ag inputs company and you will not see a strategy. You will see a list of projects. Each one has a sponsor, a slide, a story about why it matters, and a budget line that survived last year because nobody wanted the fight to kill it.

The almond program is in because a regional manager believes in it. The tomato variety stays because it fits the sub-segment. A legacy fungicide keeps its full support because it always has. None of this is strategy. It is the sum of everyone's enthusiasm, weighted by who argued hardest. And it is the single most common way good companies quietly waste capital: not on bad projects, but on a portfolio that nobody ever actually chose.

Capital allocation is the real job. Not picking projects, but deciding where the company's money, people and management attention should go, and being willing to say no to the rest. That decision needs an anchor that is harder to argue with than a sponsor's conviction. For me, that anchor is a simple chart.

None of this is new. The big consultancies built these bubble charts decades ago, attractiveness on one axis, competitive position on the other, the prize in the size of the bubble. Then most companies filed them under "nice framework" and went back to running the portfolio on conviction. The tool was never the problem. The problem is that it gets quietly abandoned the moment project championship walks into the room, because a chart that says no is less fun than a sponsor who says yes. So this is not a new model. It is how to actually use the old one, and why it keeps not getting used.

Two overarching questions, not twenty

Strip the portfolio review down and there are really only two questions worth asking about any crop, segment or product line.

The first is about the outside world. How attractive is this market? Size, growth, the margin pool, unmet agronomic need, the regulatory outlook, crop value, how crowded it already is. This is the part you do not control. It is simply true or not true.

The second is about you. What is your right to win here? Some people call it ability to serve, some call it right to win. It is the same idea: do you actually have what it takes to capture this market. Germplasm, registrations, formulation, sourcing, channel access, crop knowledge, technical support, speed to market. This is the part you do control, or can build, over time.

Almost every other metric people bring to a portfolio review is a proxy for one of these two. So plot them. Market attractiveness up the vertical axis, right to win across the horizontal. Every crop or segment becomes a point. And the moment you do that, the list of projects turns into a map.

MARKET ATTRACTIVENESS RIGHT TO WIN high low weak strong Avoid or watch attractive, but no right to win Priority bets where the future lives Low priority unattractive and weak Defend & harvest the cash is here today Blueberry Potato underfunded bet Legacy fungicide Silage corn Bubble size = realistic 3-5 year reachable margin
The portfolio on one page. Position tells you the quadrant; bubble size tells you the prize.

The four quadrants

The chart splits into four zones, and each one demands a different kind of money.

Top right: priority bets. Attractive market, and you have or can build the right to win. This is where the future of the company lives. Potato could fit here for a crop-protection portfolio: real disease pressure, a genuine need for fungicides and nematicides, a crop where technical advice matters and registrations are a moat you can actually own. These deserve disproportionate investment, because this is where attractive markets meet a credible chance of winning them.

Bottom right: defend and harvest. You are strong, but the market is mature or slow. This is where the money is today. It funds everything else. The mistake is not investing here, it is over-investing, pouring growth capital into a position that will only ever defend. Fund it to hold the line and throw off cash. Do not pretend it is a growth story.

Top left: avoid or watch. Attractive market, but you have no real right to win. This is the most dangerous quadrant, because attractiveness is seductive. Blueberry can look like this: a premium export crop with a real margin pool, but if you lack the registrations, the residue positioning and the specialist channel, you are buying a ticket to a race you cannot finish. Either build the right to win deliberately, with eyes open about the cost and the years it takes, or stay out. What you must not do is fund it halfway and call it strategy.

Bottom left: low priority. Unattractive and you are weak. Be honest and stop spending here. This may be a small silage corn seeds market in Eastern Canada: a specialty niche and you don't have the germplasm to compete. There is no shame in it. There is only shame in keeping it on life support because someone once championed it.

The bubble is the whole point

Here is where the chart earns its keep. The position tells you the quadrant. The size of the bubble tells you the prize.

Make the bubble the realistic three to five year margin potential, not total global market size. Not the headline TAM that makes everyone feel good in the deck. The practical margin you could actually capture given your position. A small, well-placed bubble in the top right can deserve more capital than a large one stuck in the wrong quadrant, because it is reachable.

And this is exactly where the statement in the title comes from. The money is in the bottom right. The opportunity is in the top right. The trap is to over-fund the first and starve the second, because today's margin shouts and tomorrow's opportunity only whispers. Good allocation funds both deliberately: enough in defend-and-harvest to keep the cash flowing, enough in the priority bets to make sure the company still exists in ten years. The chart will not make that choice for you. But it will not let you make it by accident either.

Where pet projects go to hide

Now go back to that portfolio review and lay the projects on the chart. Two things happen, and both are uncomfortable.

You find priority bets that are underfunded. The genuinely attractive markets where you have a real right to win, getting a fraction of the capital they deserve, because the sponsor is junior or quiet or the crop is unglamorous.

And you find the pet projects. Almost always top left or bottom left. The crop someone loves, the segment that tested the brand into a category it has no right to win, the program kept alive by one believer. On the chart, with the bubble sized honestly, the case collapses. Not because anyone is wrong about the crop being interesting. Because interesting is not the same as winnable, and winnable is not the same as worth the money.

That is the real value of putting it on one page. It moves the conversation from "who believes in this" to "where does it actually sit, and how big is the reachable prize." Those are answerable questions. Conviction is not.

How to use it without fooling yourself

The chart is only as honest as the inputs, so a few rules.

Score the two axes separately and before you look at the picture. The fastest way to ruin this exercise is to decide where you want a crop to land and then reverse-engineer the scores. Rate attractiveness on the market alone. Rate right to win on your real position today, not the one you hope to have after three years of investment you have not committed to yet.

Size the bubble on reachable margin, and write down the assumption. Country, crop acreage, registrations you actually hold, channel you actually have. If the bubble is big only because you assumed a registration you do not have, that belongs in a different exercise.

Then let the chart start the argument, not end it. It is a way to make the portfolio visible and force a real allocation conversation, not an oracle. The judgment is still yours. But now it is judgment about positions, not a popularity contest between projects.

Then level up

The chart gives you focus. Focus is not yet a strategy. Once you know which bets are priority and which positions only defend, the next job is to step back and ask what that focus actually demands of the company. The portfolio choice is the input. The business strategy and the key strategic drivers are what should fall out of it.

This is the part most reviews skip. They pick the focus and then keep running the same company. But a focus means something. If your priority bets sit in high-value fungicides on potato, then your strategic drivers are not generic. They become specific: depth in disease control, a registration engine that can keep the moat alive, a technical sales force that can actually carry the advice, maybe a different way to reach the grower. If the focus is somewhere else, the drivers are different again. The point is that the chosen quadrant should rewrite where you build capability, what you go to market with, who you hire, and just as importantly what you stop doing.

So treat the chart as the start of a chain, not the end of it. Focus drives strategy, strategy drives the handful of things you must be genuinely good at, and those drive the budget, the org and the roadmap. Skip the level-up and you get the worst of both worlds: a portfolio you finally chose, sitting on top of a company still built for the one you used to have.

The framework was never missing. The willingness to let it overrule a champion was.

When the chart and the budget disagree, the budget is usually the thing that needs to change. That is the whole point of doing this. Bring the willingness to let the chart overrule a champion, and the old bubble chart finally does the job it was built for.

Michiel de Jongh
Michiel de Jongh
Founder & CEO, Valorem Management

Former Country President at Monsanto and Global Head SeedCare at Syngenta. Valorem works with growth-stage agricultural innovation companies on commercial strategy, market entry, and go-to-market execution.

Get in touch →